Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 21761949)

1.

Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization.

Bryson WC, McConnell J, Korthuis PT, McCarty D.

Am J Manag Care. 2011 Jun;17 Suppl 8:S222-34.

2.

Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.

Baser O, Chalk M, Rawson R, Gastfriend DR.

Am J Manag Care. 2011 Jun;17 Suppl 8:S222-34.

PMID:
21761948
3.

Cost and utilization outcomes of opioid-dependence treatments.

Baser O, Chalk M, Fiellin DA, Gastfriend DR.

Am J Manag Care. 2011 Jun;17 Suppl 8:S235-48.

PMID:
21761950
4.

Comparison of healthcare utilization among patients treated with alcoholism medications.

Mark TL, Montejano LB, Kranzler HR, Chalk M, Gastfriend DR.

Am J Manag Care. 2010;16(12):879-88.

5.

Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.

Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR.

J Subst Abuse Treat. 2014 Aug;47(2):113-21. doi: 10.1016/j.jsat.2014.03.007. Epub 2014 Apr 13.

PMID:
24854219
6.

Utilization patterns of extended-release naltrexone for alcohol dependence.

Jan S, Gill P, Borawala AS.

Am J Manag Care. 2011 Jun;17 Suppl 8:S210-2.

PMID:
21761946
7.

Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population.

Kranzler HR, Montejano LB, Stephenson JJ, Wang S, Gastfriend DR.

Alcohol Clin Exp Res. 2010 Jun;34(6):1090-7. doi: 10.1111/j.1530-0277.2010.01185.x. Epub 2010 Apr 5.

8.

Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS.

Alcohol Clin Exp Res. 2009 Feb;33(2):350-6. doi: 10.1111/j.1530-0277.2008.00843.x. Epub 2008 Nov 25.

9.

Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR.

Alcohol Clin Exp Res. 2011 Oct;35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16.

PMID:
21575016
10.

Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR.

Addiction. 2008 Nov;103(11):1801-8. doi: 10.1111/j.1360-0443.2008.02345.x.

11.
12.

Opioid antagonists for alcohol dependence.

Srisurapanont M, Jarusuraisin N.

Cochrane Database Syst Rev. 2002;(2):CD001867. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD001867.

PMID:
12076425
13.

Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Mannelli P, Wu LT, Peindl KS, Swartz MS, Woody GE.

Drug Alcohol Depend. 2014 May 1;138:83-8. doi: 10.1016/j.drugalcdep.2014.02.002. Epub 2014 Feb 15.

14.

Early treatment response in alcohol dependence with extended-release naltrexone.

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.

J Clin Psychiatry. 2008 Feb;69(2):190-5.

PMID:
18348601
15.

Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.

DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):48-54. doi: 10.1016/j.drugalcdep.2011.06.023. Epub 2011 Jul 22.

16.

Intramuscular extended-release naltrexone: current evidence.

Gastfriend DR.

Ann N Y Acad Sci. 2011 Jan;1216:144-66. doi: 10.1111/j.1749-6632.2010.05900.x. Review. Erratum in: Ann N Y Acad Sci. 2011 Apr;1224(1):207.

PMID:
21272018
17.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
18.

Extended-release naltrexone for treatment of alcohol dependence in primary care.

Lee JD, Grossman E, DiRocco D, Truncali A, Hanley K, Stevens D, Rotrosen J, Gourevitch MN.

J Subst Abuse Treat. 2010 Jul;39(1):14-21. doi: 10.1016/j.jsat.2010.03.005. Epub 2010 Apr 2.

PMID:
20363090
19.

Opioid antagonists for alcohol dependence.

Srisurapanont M, Jarusuraisin N.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001867. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD001867.

PMID:
15674887
20.

Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W.

Contemp Clin Trials. 2013 Mar;34(2):196-204. doi: 10.1016/j.cct.2012.11.002. Epub 2012 Nov 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk